Results 91 to 100 of about 34,139,948 (244)

Survodutide - Novel Anti Obesity Drug

JK Science
Survodutide (BI 456906) is a novel, dual agonist of glucagon and glucagon-like peptide-1 (GLP-1) receptors developed as a once-weekly subcutaneous injection for the management of obesity.
Irtiqa Ayani Rathore, Sana Malik, Amarjeet Singh, Vishal R Tandon, Annil Mahajan   +4 more
doaj  

Effects of exendin-4, a glucagon like peptide-1 receptor agonist, on neutrophil count and inflammatory cytokines in a rat model of endotoxemia

, 2015
Ofer Yanay,1,2 Adam L Bailey,3 Kelly Kernan,1 Jerry J Zimmerman,1,2 William R Osborne1 1Department of Pediatrics, University of Washington, 2Division of Pediatric Critical Care Medicine, Seattle Children's Hospital, Seattle, WA, 3Medical Scientist ...
Osborne WR, Yanay O, Bailey AL, Zimmerman JJ, Kernan K   +4 more
core  

Empirically Defining “Recurrent” Inappropriate Compensatory Behaviors: Differentiating Binge Eating Disorder From Bulimia Nervosa‐Spectrum Disorders

International Journal of Eating Disorders, EarlyView.
ABSTRACT Objective For multiple disorders, DSM‐5‐TR criteria include “recurrent” engagement in behaviors—for example, in the criteria for binge‐eating disorder (BED), “binge eating is not associated with the recurrent use of inappropriate compensatory behavior.”—without operationalizing how frequently a behavior needs to occur to be considered ...
Sophie R. Abber, Dan V. Blalock, Renee D. Rienecke, Philip S. Mehler, Alan Duffy, Jamie Manwaring, Maryrose Bauschka, Kimberly Anderson, Harry A. Brandt, Craig Johnson, Timothy Brewerton, Thomas E. Joiner, Lauren N. Forrest   +12 more
wiley   +1 more source

Tirzepatide-induced ketoacidosis in non-diabetic patients

European Journal of Case Reports in Internal Medicine
Background: Tirzepatide is a novel glucagon-like peptide 1/glucose-dependent insulinotropic peptide (GLP-1/GIP) receptor agonist. It was recently approved for diabetes control and weight reduction in non-diabetic patients. Case description: We report the
Pathan Mohamad Rafe Iqbal, Ossama Sajeh Maadarani, Zouheir Ibrahim Bitar   +2 more
doaj   +1 more source

Connecting the dots: A narrative review of the relationship between heart failure and cognitive impairment

ESC Heart Failure, Volume 12, Issue 2, Page 1119-1131, April 2025.
Abstract Large clinical data underscore that heart failure is independently associated to an increased risk of negative cognitive outcome and dementia. Emerging evidence suggests that cerebral hypoperfusion, stemming from reduced cardiac output and vascular pathology, may contribute to the largely overlapping vascular dementia and Alzheimer's disease ...
Mauro Massussi, Maria Giulia Bellicini, Marianna Adamo, Andrea Pilotto, Marco Metra, Alessandro Padovani, Riccardo Proietti   +6 more
wiley   +1 more source

Glucagon-Like Peptide-1 Agonists to Manage Weight Gain in Patients Taking Antipsychotics [poster] [PDF]

Patients struggling with schizophrenia have significant weight gain and lower life expectancy than the general population. These differences may be the result of commonly prescribed antipsychotic medications.
Nash, Samuel
core   +1 more source

Association between glucagon-like peptide-1 receptor agonist use and peri-operative pulmonary aspiration: a systematic review and meta-analysis

INTRODUCTION: Glucagon-like peptide-1 receptor agonists are known to delay gastric emptying; however, the association between glucagon-like peptide-1 receptor agonist use and peri-operative pulmonary aspiration risk is not known.
Choong, P, Shadbolt, C, Hii, M, Dowsey, M, Sumithran, P, Rele, S, Thuraisingam, S, Spelman, T, Elkin, J, Phan, T   +9 more
core   +1 more source

Semaglutide normalizes increased cardiomyocyte calcium transients in a rat model of high fat diet‐induced obesity

ESC Heart Failure, Volume 12, Issue 2, Page 1386-1397, April 2025.
Sequeira et al. reveal how the glucagon‐like peptide‐1 receptor agonist (GLP‐1‐RA) semaglutide restores cardiomyocyte function in rats subjected to a high‐fat/high‐fructose diet (HFD). Employing fluorescence‐ and patch‐clamp technology in isolated cardiac myocytes, they demonstrate that semaglutide reverses HFD‐induced activation of L‐type calcium ...
Vasco Sequeira, Julia Theisen, Katharina J. Ermer, Marie Oertel, Anton Xu, David Weissman, Katharina Ecker, Jan Dudek, Martin Fassnacht, Alexander Nickel, Michael Kohlhaas, Christoph Maack, Ulrich Dischinger   +12 more
wiley   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

Should glucagon‐like peptide‐1 receptor agonist treatment be withheld in preoperative management?

Journal of Diabetes, 2023
Zachary Bloomgarden
doaj   +1 more source